| Literature DB >> 23188186 |
Peter White1, Kit Chi Chan, Ka Wai Cheng, Ka Yiu Chan, Ming Chun Chau.
Abstract
Dosimetric comparisons between RapidArc (RA) and conventional Intensity-Modulated Radiation Therapy (IMRT) techniques for nasopharyngeal carcinoma (NPC) were performed to address differences in dose coverage of the target, sparing of organs-at-risk (OARs), delivery of monitor units (MUs) and time, to assess whether the RA technique was more beneficial for treatment of NPC. Eight NPC patients (Stages I-IV), who had completed RA treatment, were selected for this study. Computed tomography data sets were re-planned using 7-fields fixed beam IMRT. Quantitative measurements of dose-endpoint values on the dose-volume histograms were carried out for evaluation of: (i) dose homogeneity (D5% - D(95%)); (ii) degree of conformity (CI9(5%)); (iii) tumor control probability (TCP); (iv) doses to OARs; (v) normal tissue complication probability (NTCP); (vi) treatment time; and (vii) MUs. RA plans achieved better dose conformity and TCP in planning target volumes (PTVs). Target dose homogeneity was not as high as for IMRT plans. Doses to tempero-mandibular joints, clavicles, parotid glands and posterior neck, and their NTCPs were significantly lower in RA plans (P < 0.05). Mean doses to the brainstem and spinal cord were slightly lower in IMRT plans. RA plans allowed for a mean reduction in MUs by 78% (P = 0.006), and a four-fold reduction in treatment delivery times, relative to IMRT plans. RA plans showed superior, or comparable, target coverage and dose conformity in PTVs, but at the expense of inferior dose homogeneity. RA plans also achieved significant improvements in dose reduction to OARs and healthy tissue sparing. A significant reduction in treatment delivery time for RA treatment technique was also noted.Entities:
Keywords: IMRT; RapidArc; dosimetry; nasopharyngeal carcinoma; planning
Mesh:
Year: 2012 PMID: 23188186 PMCID: PMC3650737 DOI: 10.1093/jrr/rrs111
Source DB: PubMed Journal: J Radiat Res ISSN: 0449-3060 Impact factor: 2.724
Patient demographics
| Gender | Age | Volumes of each PTV (cm3) | ||||||
|---|---|---|---|---|---|---|---|---|
| PTV54 | PTV56 | PTV62 | PTV70 | PTV74 | ||||
| Stage I | P1 | M | 64 | – | 151.3 | 610.1 | 435.4 | 154.2 |
| P2 | M | 84 | 200.7 | – | – | – | – | |
| Stage II | P3 | F | 64 | – | 148.5 | 491.9 | 405.8 | 163.8 |
| P4 | M | 78 | 204.6 | 10.9 | 372.2 | 107.9 | 68.9 | |
| Stage III | P5 | F | 38 | – | 123.4 | 504.7 | 316.3 | 213.5 |
| P6 | F | 44 | 18.9 | 203.6 | 439.1 | 154.3 | 76.7 | |
| Stage IV | P7 | F | 71 | – | 274.3 | 491.7 | 371.4 | 224.8 |
| P8 | M | 73 | – | 464.8 | 584 | 297 | 196.1 | |
PTV74, PTV70, PTV62, PTV56 and PTV54 = Planning Target Volumes (PTV) being prescribed with 74 Gy, 70 Gy, 62 Gy, 56 Gy and 54 Gy, respectively.
Acceptance criteria for Organs-At-Risk (OARs)
| OARs | Specification | Reference |
|---|---|---|
| Brainstem | Dmax < 54 Gy | RTOG |
| PRV of brainstem | 1% vol < 60 Gy (preferable: 54 Gy vol <5%) | RTOG |
| Spinal cord | Dmax < 45 Gy | RTOG |
| PRV of spinal cord | 1% vol < 50Gy (preferable: 45 Gy vol <3%) | RTOG |
| Chiasm | Dmax < 54 Gy | PWH |
| Lt and Rt optic nerve | Dmax < 54 Gy | PWH |
| Lt and Rt eyeball | Dmax < 54 Gy (RTOG < 50 Gy) | PWH |
| Lt and Rt lens | Dmax < 10 Gy (RTOG < 25 Gy) | PWH |
| Lt and Rt temporal lobe (TML) | Dmax < 72 Gy or <4 cm3 vol > 60 Gy | PWH |
| Lt and Rt parotid gland | Dmean < 26 Gy or 50% vol < 30 Gy | RTOG |
| Combined parotid glands | >20 cm3 vol received < 20 Gy | RTOG |
| Lt and Rt VIIIn and cochlea | <5% vol > 55 Gy or Dmean < 50 Gy | RTOG |
| Lt and Rt brachial plexus | Dmax < 66 Gy | RTOG |
| Laryngo-pharynx | Dmean < 45 Gy | RTOG |
| Lt and Rt TMJ | Dmax < 70 Gy or <1 cm3 vol > 75 Gy | RTOG |
| Oral cavity/trachea–oesophagus | Dmean < 40 Gy | RTOG |
| Unspecified tissues outside target: Posterior Brain, Posterior Neck | <5% vol > 70 Gy or <1%/1cm3 vol > 70 Gy | RTOG |
Dmax = Maximum Dose, Dmean = Mean dose, PRV = Planning Organ-at-Risk Volume, VIIIn = Auditory nerve, TMJs = tempero-mandibular joints, RTOG = Radiation Therapy Oncology Group, PWH = Prince of Wales Hospital.
Comparison of the percentage volume of targets receiving 95% of the prescribed doses (V95%) and dose homogeneity of multiple targets (PTV54, PTV56, PTV62, PTV70 & PTV74) between RA plans and IMRT plans
| V95% (%) | Dose homogeneity (D5% – D95%) | ||||
|---|---|---|---|---|---|
| RA Plans | IMRT Plans | RA Plans | IMRT Plans | ||
| PTV54 | 99.66 | 99.83 | 5.95 ± 1.37 | 7.44 ± 3.28 | 0.143 |
| PTV56 | 99.8 | 99.91 | 5.12 ± 0.92 | 4.00 ± 1.54 | |
| PTV62 | 99.77 | 99.91 | 9.26 ± 1.62 | 8.65 ± 1.23 | 0.20 |
| PTV70 | 99.73 | 99.9 | 7.11 ± 1.20 | 6.94 ± 0.99 | 0.43 |
| PTV74 | 99.75 | 99.91 | 4.43 ± 0.83 | 4.87 ± 1.05 | 0.43 |
*Significant at P < 0.05. PTV74, PTV70, PTV62, PTV56 and PTV54 = Planning Target Volumes (PTV) being prescribed with 74 Gy, 70 Gy, 62 Gy, 56 Gy and 54 Gy, respectively. D5% – D95% = difference between the dose received by the 5% and 95% volume of the PTV.
Fig. 1.Comparison of DVHs of targets (PTV 56, PTV 62, PTV 70 and PTV 74) between RA plan and IMRT plan of a stage IV patient.
Comparison of Conformity Index (CI95%) and Tumor Control Probability (TCP) of targets (PTV56, PTV62, PTV70 and PTV74) between RA plans and IMRT plans
| Conformity Index (CI95%) | TCP (%) | ||||||
|---|---|---|---|---|---|---|---|
| RA Plans | IMRT Plans | Relative decrease† | RA Plans | IMRT Plans | |||
| PTV56 | 3.98 ± 1.33 | 4.68 ± 1.84 | 0.09 | 14.96% | 86.1 ± 7.62 | 84.29 ± 8.19 | |
| PTV62 | 1.72 ± 0.13 | 1.85 ± 0.33 | 0.09 | 7.03% | 89.24 ± 3.83 | 88.38 ± 5.56 | 0.36 |
| PTV70 | 2.03 ± 0.51 | 2.10 ± 0.70 | 0.16 | 3.33% | 96.34 ± 1.12 | 96.33 ± 1.02 | 0.34 |
| PTV74 | 3.13 ± 0.54 | 3.34 ± 0.59 | 0.06 | 6.29% | 98.73 ± 0.39 | 98.58 ± 0.43 | |
*Significant at P < 0.05. †Relative decrease = (RA Plans – IMRT Plans)/IMRT Plans × 100%. CI95% = ratio between the patient volume receiving at least 95% of the prescribed dose and the volume of the PTV.
Comparison of doses to OARs and the corresponding Normal Tissue Complication Probability (NTCP) between RA plans and IMRT plans
| Dose to OARs (Gy) | NTCP (%) | |||||
|---|---|---|---|---|---|---|
| RA Plans | IMRT Plans | RA Plans | IMRT Plans | |||
| Spinal cord (D1%) | 44.27 ± 2.57 | 43.43 ± 2.16 | 0.08 | 0.85 ± 0.20 | 0.51 ± 0.38 | |
| Brainstem (D1%) | 54.09 ± 1.60 | 53.45 ± 3.59 | 0.31 | 0.30 ± 0.20 | 0.18 ± 0.24 | 0.10 |
| Chiasm (D1%) | 39.84 ± 18.52 | 46.17 ± 20.97 | 0.10 | 2.98 ± 4.23 | 6.76 ± 10.51 | 0.05 |
| Lt tempero-mandibular joint (D1%) | 63.40 ± 7.79 | 66.28 ± 5.39 | 1.99 ± 3.07 | 3.88 ± 5.55 | ||
| Clavicle (D1%) | 60.62 ± 0.99 | 62.47 ± 1.91 | 15.62 ± 14.75 | 15.78 ± 14.00 | 0.17 | |
| Mandible (D1%) | 78.16 | 81.45 | N/A | N/A | N/A | N/A |
| Post brain (D1%) | 69.65 ± 2.51 | 73.78 ± 3.02 | 0.36 ± 0.39 | 0.66 ± 0.57 | ||
| Post neck 1 (D1%) | 63.91 ± 3.32 | 70.11 ± 7.24 | 0.09 ± 0.07 | 0.29 ± 0.27 | ||
| Post neck 2 (D1%) | 70.14 ± 2.22 | 78.21 ± 4.40 | 1.50 ± 0.95 | 7.16 ± 5.30 | ||
| Laryngo-pharynx (Dmean) | 51.22 ± 3.42 | 43.69 ± 5.54 | 1.43 ± 4.03 | 2.65 ± 7.50 | 0.33 | |
| Trachea-oesophagus (Dmean) | 45.76 ± 2.67 | 47.30 ± 4.45 | 0.11 | 3.78 ± 3.41 | 6.78 ± 5.45 | |
| Lt temporal lobe (D1%) | 70.00 ± 3.43 | 71.33 ± 3.12 | 4.18 ± 6.80 | 6.64 ± 12.06 | 0.06 | |
| Lt cochlea (Dmean) | 52.39 ± 7.47 | 47.47 ± 8.91 | N/A | N/A | N/A | |
| Lt auditory nerve (Dmean) | 52.55 ± 8.98 | 46.59 ± 10.56 | N/A | N/A | N/A | |
| Combined parotid gland (vol < 20 Gy)† | 10.21 ± 7.53 | 1.87 ± 2.30 | N/A | N/A | N/A | |
*Significant at P < 0.05. †Volume of combined parotid glands receiving < 20 Gy (cm3).
Fig. 2.Comparison of DVHs of spinal cord and brainstem between RA plan and IMRT plan of a stage IV patient.
Fig. 3.Comparison of DVHs of posterior brain tissues, post neck 1 and post neck 2 between RA plan and IMRT plan of a stage IV patient.